Vantage logo

The patent winter is coming

Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?

Vantage logo

What’s next for relatlimab?

The Lag3 inhibitor is now approved in melanoma, but Bristol looks unlikely to stop there in its search for a safer Yervoy.

Vantage logo

Medicare’s new devices

A handful of medtechs will benefit from new reimbursement pathways – but others have been denied the chance.